Maternal serum pregnancy-associated plasma protein-A and free β-human chorionic gonadotrophin in pregnancies conceived with fresh and frozen-thawed embryos from in vitro fertilization and intracytoplasmic sperm injection

Prenatal Diagnosis

Volumn 25, Issue 5, 2005, Pages 390-393

  Hui, Pui Wah ^a   Lam, Yung Hang ^b   Tang, Mary Hoi Yin ^a   Ng, Ernest Hung Yu ^a   Yeung, William Shu Biu ^a   Ho, Pak Chung ^b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

FET; hCG; ICSI; IVF; PAPP A

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN SYNDROME; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FETUS; FIRST TRIMESTER PREGNANCY; FLUOROMETRY; FREEZE THAWING; GESTATIONAL AGE; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CRYOPRESERVATION; DOWN SYNDROME; EMBRYO; FEMALE; FERTILIZATION IN VITRO; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 20444459752     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1169     Document Type: Article

References (45)

1. Barkai G, Goldman B, Ries L, et al. 1996. Down's syndrome screening marker levels following assisted reproduction. Prenat Diagn 16: 1111-1114.
2. Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. 1997. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. Br J Obstet Gynaecol 104: 811-817.
3. Bersinger NA, Wunder D, Vanderlick F, et al. 2004. Maternal serum levels of placental proteins after in vitro fertilisation and their implications for prenatal screening. Prenat Diagn 24: 471-477.
4. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 20: 219-225.
5. Brambati B, Macintosh MC, Teisner B, et al. 1993. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 100: 324-326.
6. Brambati B, Tului L, Bonacchi I, Shrimanker K, Suzuki Y, Grudzinskas JG. 1994. Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome. Prenat Diagn 14: 1043-1047.
7. Canick JA, Kellner LH. 1999. First trimester screening for aneuploidy: serum biochemical markers. Semin Perinatal 23: 359-368.
8. Cuckle H. 1992. Screening for Down's syndrome. Br Med J 305: 1504.
9. de Graaf IM, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, van Lith JM. 2000. Co-variables in first trimester maternal serum screening. Prenat Diagn 20: 186-189.
10. Folkersen J, Grudzinskas JG, Hindersson P, Teisner B, Westergaard JG. 1981. Pregnancy-associated plasma protein A: circulating levels during normal pregnancy. Am J Obstet Gynecol 139: 910-914.
11. Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner LH, Sailer DN Jr. 1997. Serum triple-marker screening in in-vitro fertilization and naturally conceived pregnancies. Obstet Gynecol 90: 98-101.
12. Ghisoni L, Ferrazzi E, Castagna C, Levi Setti PE, Masini AC, Pigni A. 2003. Prenatal diagnosis after ART success: the role of early combined screening tests in counselling pregnant patients. Placenta 24(Suppl. B): S99-S103.
13. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. 1998. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 338: 955-961.
14. Heinonen S, Ryynanen M, Kirkinen P, et al. 1996. Effect of in vitro fertilization on human chorionic gonadotrophin serum concentrations and Down's syndrome screening. Fertil Steril 66: 398-403.
15. Hemmilä I, Dakubu S, Mukkala V-M, Siitari H, Lövgren T. 1984. Europium as a label in time-resolved immunofluorometric assays. Anal Biochem 137: 335-343.
16. Hsu JJ, Hsieh TT, Hsieh FJ. 1996. Down syndrome screening in an Asian population using alpha-fetoprotein and free β-hCG: a report of the Taiwan Down syndrome screening group. Obstet Gynecol 87: 943-947.
17. Hui PW, Tang MH, Lam YH, Ng EH, Yeung WS, Ho PC. 2003. Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos. Hum Reprod 18: 572-575.
18. Lam SK, To WK, Duthie SJ, Ma HK. 1992. The effect of smoking during pregnancy on the incidence of low birth weight among Chinese parturients. Aust NZJ Obstet Gynaecol 32: 125-128.
19. Lam YH, Yeung WSB, Tang MHY, Ng EH, So WW, Ho PC. 1999. Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in-vitro fertilization. Hum Reprod 14: 2120-2123.
20. Lam YH, Ghosh A, Tang MHY, et al. 1998. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong. Prenat Diagn 18: 585-589.
21. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. 2001. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 16: 1501-1504.
22. Lin TM, Haibert SP. 1976. Placental localization of human pregnancy-associated plasma proteins. Science 193: 1249-1252.
23. May mon R, Shulman A. 2001. Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. Hum Reprod 16: 691-695.
24. Maymon R, Shulman A. 2002. Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 17: 1081-1085.
25. Meschede D, Lemcke B, Stussel J, Louwen F, Horst J. 1998. Strong preference for non-invasive prenatal diagnosis in women pregnant through intracytoplasmic sperm injection. Prenat Diagn 18: 700-705.
26. Mulvey S, Wallace EM. 2000. Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. Br J Obstet Gynecol 107: 1302-1305.
27. Ng EHY, Yeung WSB, Lau EYL, So WW, Ho PC. 2000. High serum oestradiol concentrations in fresh IVF cycles do not impair implantation and pregnancy rates in subsequent frozen-thawed embryo transfer cycles. Hum Reprod 15: 250-255.
28. Niemimaa M, Heinonen S, Seppala M, Ryynanen M. 2003. The influence of smoking on the pregnancy-associated plasma protein A, free beta human chorionic gonadotrophin and nuchal translucency. BJOG 110: 664-667.
29. Niemimaa M, Heinonen S, Seppala M, Hippelainen M, Martikainen H, Ryynanen M. 2001. First-trimester screening for Down's syndrome in in vitro fertilization pregnancies. Fertil Steril 76: 1282-1283.
30. Onda T, Kitagawa M, Takeda O, et al. 1996. Triple marker screening in native Japanese women. Prenat Diagn 16: 713-717.
31. Orlandi F, Rossi C, Allegra A, et al. 2002. First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 22: 718-721.
32. Palomaki GE, Knight GJ, McCarthy J, Haddow JE, Eckfeldt JH. 1993. Maternal serum screening for fetal Down syndrome in the United States: a 1992 survey. Am J Obstet Gynecol 169: 1558-1562.
33. Perheentupa A, Ruokonen A, Tuomivaara L, Ryynanen M, Martikainen H. 2002. Maternal serum β-hCG and a-fetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod 17: 794-797.
34. Raty R, Virtanen A, Koskinen P, et al. 2002. Serum free β-hCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome. Hum Reprod 17: 481-484.
35. Ribbert LS, Kornman LH, De Wolf BT, et al. 1996. Maternal serum screening for fetal Down syndrome in IVF pregnancies. Prenat Diagn 16: 35-38.
36. Schover LR, Thomas AJ, Falcone T, Attaran M, Goldberg J. 1998. Attitudes about genetic risk of couples undergoing in-vitro fertilization. Hum Reprod 13: 862-866.
37. Spencer K. 1999. The influence of smoking on maternal serum PAPP-A and free beta-hCG levels in the first trimester of pregnancy. Prenat Diagn 19: 1065-1066.
38. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
39. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 110: 281-286.
40. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000a. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynecol 107: 1271-1275.
41. Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH. 2000b. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 673-675.
42. Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH. 2000c. First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status. Prenat Diagn 20: 852-853.
43. Wald NJ, George L, Smith D, Densem JW, Petterson K. 1996. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International prenatal screening research group. Br J Obstet Gynaecol 103: 407-412.
44. Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. 1999. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 106: 1304-1306.
45. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. SURUSS Research Group. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess. 7: 1-77.